Company: AZN
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001654954-25-001920
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-02-26
Form: 6-K
Chunk 5
---
 of Datrowayalone and in combination with immunotherapy Imfinzi(durvalumab).

#### AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Companyon social media @ AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### References
1. Cerner CancerMPact database. Accessed February 2025.

2. Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer . 2020; 10.7150/jca.48944.

3. Lloyd M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res . 2022; 28(5):821-30.

4. Brett O, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor - positive breast cancer. Breast Cancer Res . 2021; 23:85.

5. Zundelevich, A, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco